Company: QTIWW
Filing Date: 2025-02-05
Form Type: 424B3
Source: 0001628280-25-004061
Chunk: 191

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-02-05
Form: 424B3
Chunk 191
---
 use because of its high performance, safety and relatively low cost. Furthermore, we believe that providing increased patient access to safe medical imaging is one important solution to increasing access and lowering the costs of medical care.

The Company intends to follow a staged entry into the market, beginning with clearances already in place which support its use as an adjunct to mammography and to monitor treatment. It will then use these placements as footholds from which to build presence in the medical community and acquire the data needed for additional FDA clearances and insurance reimbursement. In parallel with these efforts, the Company will solidify existing business and distribution strategic partnerships to cover sales in US, as well as partnerships to build strong manufacturing processes to deliver the QT Breast Scanners in large scale production.

<div align='center'>118</div>

#### Our Competitive Strengths
We believe that our competitive strengths include the following:

• The world-wide market for medical imaging is large and it has a potential to expand in the areas where the Company has differentiation;

• a non-ionizing, non-contrast dye injection imaging modality;

• an imaging modality with superior performance as compared to traditional mammogram with respect to specificity (false positive), thus less unnecessary emotional trauma for patients, reduced numbers of invasive follow-up procedures and a reduction of costs for both patient and broader society;

• a lower price point than conventional high-energy imaging equipment;

• the Company’s technology can be deployed to LREs because of its automation, small footprint, no shielding, no contrast-dye injection;

• the Company’s technology is portable and can be used in POC settings such as LREs;

• the Company’s technology is deployable in outdoor settings such as sports, military, and naval settings;

• the Company’s technology reduces the barriers to testing and follow up-care for women, as there is no need for specialized training and the technology is well-suited for lowering health care costs by being affordable and easily accessed;

• the Company’s technology provides optimized patient experience, as no radiation is involved, with the patient being able to be followed with no limitation to imaging frequency;

• the Company’s technology is well-suited for traditional tertiary care hospitals and additionally for DTC and DTP applications, that are outside these institutions;

• the Company’s technology is uniquely proprietary, disruptive and a one-of-a kind product that can address a variety of unmet medical needs in the medical marketplace;

• the Company’s scanner features a uniquely simple design with a small number of components, which in turn significantly reduces the cost of the